If systemic CRS appears during CAR-T cell therapy, it is recommended that TCZ, a monoclonal antibody against the interleukin-6 receptor, be used as soon as possible.[15] However, the effect of TCZ on L-CRS may be limited. Here, IL6R is linked to congenital rubella syndrome.